Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth

Nature Communications

Volumn 6, Issue , 2015, Pages

  Vallabhapurapu, Subrahmanya D ^a   Noothi, Sunil K ^a   Pullum, Derek A ^a   Lawrie, Charles H ^b,c   Pallapati, Rachel ^a   Potluri, Veena ^a   Kuntzen, Christian ^d   Khan, Sohaib ^a   Plas, David R ^a   Orlowski, Robert Z ^e   Chesi, Marta ^f   Kuehl, W Michael ^g   Bergsagel, P Leif ^f   Karin, Michael ^h   Vallabhapurapu, Sivakumar ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d BRIDGEPORT HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f MAYO CLINIC   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; HISTONE DEACETYLASE 4; MICRORNA 221; POLYPEPTIDE; PROTEIN P52; TRANSCRIPTION FACTOR RELB; APOPTOSIS REGULATORY PROTEIN; BCL2L11 PROTEIN, HUMAN; BCL2L11 PROTEIN, MOUSE; BIM PROTEIN; BMF PROTEIN, HUMAN; HDAC4 PROTEIN, HUMAN; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; MICRORNA; MIRN221 MICRORNA, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 3; ONCOPROTEIN; RELB PROTEIN, HUMAN; REPRESSOR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

CELLS AND CELL COMPONENTS; ENZYME ACTIVITY; GENE EXPRESSION; GROWTH; METABOLISM; PEPTIDE; PHYSIOLOGY; PROTEIN; SURVIVAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIM GENE; BMF GENE; CANCER GROWTH; CANCER SURVIVAL; CHROMATIN; CONTROLLED STUDY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PLASMA CELL; PROTEIN PROTEIN INTERACTION; TRANSLATION REGULATION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PHOSPHORYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS REGULATORY PROTEINS; BCL-2-LIKE PROTEIN 11; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; MALE; MEMBRANE PROTEINS; MICE, NUDE; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASE 3; MULTIPLE MYELOMA; NF-KAPPA B P52 SUBUNIT; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; TRANSCRIPTION FACTOR RELB;

EID: 84943751349     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9428     Document Type: Article

References (66)

1. Kuehl, W. M., Bergsagel, P. L. Multiple myeloma: evolving genetic events and host interactions. Nat. Rev. Cancer 2, 175-187 (2002).
2. Chng, W. J., Glebov, O., Bergsagel, P. L., Kuehl, W. M. Genetic events in the pathogenesis of multiple myeloma. Best Pract. Res. Clin. Haematol. 20, 571-596 (2007).
3. Fonseca, R. et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23, 2210-2221 (2009).
4. Kuehl, W. M., Bergsagel, P. L. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology. Am. Soc. Hematol. Educ. Program 346-352 (2005).
5. Chng, W. J., Kuehl, W. M., Bergsagel, P. L., Fonseca, R. Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature. Leukemia 22, 459-461 (2008).
6. Kuehl, W. M., Bergsagel, P. L. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J. Clin. Invest. 122, 3456-3463 (2012).
7. Zhan, F. et al. The molecular classification of multiple myeloma. Blood 108, 2020-2028 (2006).
8. Vallabhapurapu, S., Karin, M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu. Rev. Immunol. 27, 693-733 (2009).
9. Karin, M. NF-kappaB and cancer: mechanisms and targets. Mol. Carcinog. 45, 355-361 (2006).
10. Naugler, W. E., Karin, M. NF-kappaB and cancer-identifying targets and mechanisms. Curr. Opin. Genet. Dev. 18, 19-26 (2008).
11. Karin, M., Cao, Y., Greten, F. R., Li, Z. W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2, 301-310 (2002).
12. Karin, M. Nuclear factor-kappaB in cancer development and progression. Nature 441, 431-436 (2006).
13. Staudt, L. M. Oncogenic activation of NF-kappaB. Cold Spring Harb. Perspect Biol. 2, a000109 (2010).
14. Lim, K. H., Yang, Y., Staudt, L. M. Pathogenetic importance and therapeutic implications of NF-kappaB in lymphoid malignancies. Immunol. Rev. 246, 359-378 (2012).
15. Perkins, N. D. The diverse and complex roles of NF-kappaB subunits in cancer. Nat. Rev. Cancer 12, 121-132 (2012).
16. Natoli, G. NF-kappaB and chromatin: ten years on the path from basic mechanisms to candidate drugs. Immunol. Rev. 246, 183-192 (2012).
17. Pahl, H. L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18, 6853-6866 (1999).
18. Gilmore, T. D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25, 6680-6684 (2006).
19. Bishton, M., Kenealy, M., Johnstone, R., Rasheed, W., Prince, H. M. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Expert Rev. Anticancer Ther. 7, 1439-1449 (2007).
20. Coolen, M. W. et al. Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat. Cell Biol. 12, 235-246 (2010).
21. Baylin, S. B. et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 10, 687-692 (2001).
22. Smale, S. T. Dimer-specific regulatory mechanisms within the NF-kappaB family of transcription factors. Immunol. Rev. 246, 193-204 (2012).
23. Annunziata, C. M. et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115-130 (2007).
24. Keats, J. J. et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12, 131-144 (2007).
25. Vallabhapurapu, S. et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat. Immunol. 9, 1364-1370 (2008).
26. Zarnegar, B. J. et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat. Immunol. 9, 1371-1378 (2008).
27. Sivakumar, V., Hammond, K. J., Howells, N., Pfeffer, K., Weih, F. Differential requirement for Rel/nuclear factor kappa B family members in natural killer T cell development. J. Exp. Med. 197, 1613-1621 (2003).
28. Yilmaz, Z. B.,Weih, D. S., Sivakumar, V.,Weih, F. RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF. EMBO J. 22, 121-130 (2003).
29. Senftleben, U. et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293, 1495-1499 (2001).
30. Hideshima, T. et al. Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood 113, 5228-5236 (2009).
31. Thompson, J. L. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. Ann. Pharmacother. 47, 56-62 (2013).
32. Moreau, P. et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120, 947-959 (2012).
33. Tan, D. et al. The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. Leuk. Res. 37, 1070-1076 (2013).
34. Laubach, J. P. et al. Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenstroms Macroglobulinemia. Leuk. Lymphoma 50, 694-702 (2009).
35. Orlowski, R. Z. Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma. Cancer Cell 24, 275-277 (2013).
36. Jagannath, S., Dimopoulos, M. A., Lonial, S. Combined proteasome and histone deacetylase inhibition: a promising synergy for patients with relapsed/refractory multiple myeloma. Leuk. Res. 34, 1111-1118 (2010).
37. Minami, J. et al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia. 28, 680-689 (2014).
38. Santo, L. et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 119, 2579-2589 (2012).
39. Matsui, W. et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 68, 190-197 (2008).
40. Leung-Hagesteijn, C. et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 24, 289-304 (2013).
41. Gramantieri, L. et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin. Cancer Res. 15, 5073-5081 (2009).
42. Huang, J. J., Yu, J., Li, J. Y., Liu, Y. T., Zhong, R. Q. Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma. Med. Oncol. 29, 2402-2408 (2012).
43. Di Martino, M. T. et al. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget 4, 242-255 (2013).
44. Neumann, M. et al. Glycogen synthase kinase-3beta is a crucial mediator of signal-induced RelB degradation. Oncogene 30, 2485-2492 (2011).
45. Wortzel, I., Seger, R. The ERK cascade: distinct functions within various subcellular organelles. Genes Cancer 2, 195-209 (2011).
46. Rocha, S., Martin, A. M., Meek, D. W., Perkins, N. D. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Mol. Cell. Biol. 23, 4713-4727 (2003).
47. Campbell, K. J., Rocha, S., Perkins, N. D. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol. Cell. 13, 853-865 (2004).
48. Fuchs, O. Transcription factor NF-kappaB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies. Curr. Mol. Pharmacol. 3, 98-122 (2010).
49. Wen, D. et al. A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblastlike synoviocytes, chondrocytes, and mast cells. J. Pharmacol. Exp. Ther. 317, 989-1001 (2006).
50. Ranuncolo, S. M., Pittaluga, S., Evbuomwan, M. O., Jaffe, E. S., Lewis, B. A. Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival. Blood 120, 3756-3763 (2012).
51. Vega, R. B. et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119, 555-566 (2004).
52. Birbach, A. et al. Signaling molecules of the NF-kappa B pathway shuttle constitutively between cytoplasm and nucleus. J. Biol. Chem. 277, 10842-10851 (2002).
53. Tan, B. T., Park, C. Y., Ailles, L. E., Weissman, I. L. The cancer stem cell hypothesis: a work in progress. Lab. Invest. 86, 1203-1207 (2006).
54. Dick, J. E. Stem cell concepts renew cancer research. Blood 112, 4793-4807 (2008).
55. Marienfeld, R. et al. Signal-specific and phosphorylation-dependent RelB degradation: a potential mechanism of NF-kappaB control. Oncogene 20, 8142-8147 (2001).
56. Richardson, P. G. et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomibrefractory myeloma. Blood 122, 2331-2337 (2013).
57. San-Miguel, J. F. et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J. Clin. Oncol. 31, 3696-3703 (2013).
58. Geng, L. et al. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res. 66, 11298-11304 (2006).
59. Demchenko, Y. N. et al. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 115, 3541-3552 (2010).
60. Bergsagel, P. L. et al. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc. Natl Acad. Sci. USA 93, 13931-13936 (1996).
61. Kuhn, D. J. et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 120, 3260-3270 (2012).
62. MacLeod, R. A., Nagel, S., Dirks, W., Drexler, H. G. BCR-ABL1 expression in multiple myeloma cells: a case of mistaken identity? Proc. Natl Acad. Sci. USA 110, E270-E271 (2013).
63. Breitkopf, S. B., Yuan, M., Pihan, G. A., Asara, J. M. Detection of a rare BCRABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS). Proc. Natl Acad. Sci. USA 109, 16190-16195 (2012).
64. Breitkopf, S. B., Yuan, M., Pihan, G. A., Asara, J. M. Reply to MacLeod et al.: multiple myeloma plasma cells have chameleon characteristics. Proc. Natl Acad. Sci. USA 110, E272 (2013).
65. Jensen, M. M., Jorgensen, J. T., Binderup, T., Kjaer, A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC. Med. Imaging 8, 16 (2008).
66. Potluri, V. et al. Transcriptional repression of Bim by a novel YY1-RelA complex is essential for the survival and growth of Multiple Myeloma. PloS ONE 8, e66121 (2013).